NEALS
Our Mission
Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible.
To achieve our goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for ALS community. Learn more about our structure.
Our Values
The NEALS consortium is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities.
History
NEALS was founded in 1995 with 9 academic clinical centers in the New England area. With help from The ALS Association’s TREAT ALS Network, Muscular Dystrophy Association, and our generous donors, the NEALS membership has grown to over 100 research centers committed to performing research in ALS and MND.
Webinar: Long-Term Survival of Participants in the CENTAUR Trial
VirtualPlease join us on Wednesday, October 21st from 2:00-3:00 p.m. for "Long-Term Survival of Participants in the CENTAUR Trial", a webinar with myself and Sabrina Paganoni, MD, Phd, principal investigator of the CENTAUR Trial, to discuss the ongoing results of the CENTAUR Trial.
NEALS – ALS Nutrition
VirtualALS Nutrition App - Cooking Demonstrations and Ask a Dietitian Session!
NEALS Webinar – Is the Key to Stopping ALS Being Flushed Down Our Toilets?
VirtualPresenter: Richard Bedlack, MD, PhD, Duke ALS Clinic The gut microbiome is the family of organisms that live inside our GI tracts. It is very clear that the gut microbiome plays a role in gastrointestinal diseases. Recently, evidence is emerging that the gut microbiome may play a role in driving ALS progression. Here we will review […]
Webinar: Home Digital Outcome Measures
VirtualHome Digital Outcome Measures Webinar hosted by NEALS, MGH, and Barrow Neurological Institute. Tuesday, December 8th from 3:00pm – 5:00pm ET. Click here to RSVP: https://www.surveymonkey.com/r/?sm=A1loKNOj9Xf2Dcw8Eg0HHA_3D_3D
Results of the REFALS Study
VirtualResults of the REFALS Study Merit Cudkowicz, MD, MSc Sean M. Healey & AMG Center for ALS at Mass General Hospital Tuesday, December 15, 2020 12:00 - 1:00 PM EST Dr. Merit Cudkowicz will review the results of the REFALS trial evaluating the effect of oral levosimendan (ODM-109) on respiratory function in people with ALS. REGISTER NOW
NEALS Webinar: Expanded Access to Investigational Drugs
VirtualExpanded Access to Investigational Drugs Friday, January 15, 2021 4:00 - 5:00 PM EST Join us for a webinar on Expanded Access Programs (EAPs). In EAPs people with ALS who are not eligible for clinical trials are provided the study medication on a compassionate use basis. Our panelists will discuss the benefits and challenges surrounding EAPs […]
NEALS Webinar: Brain-Computer Interfaces Toward the Maintenance and Restoration of Communication and Mobility
VirtualBrainGate: Brain-Computer Interfaces Toward the Maintenance and Restoration of Communication and Mobility Leigh R. Hochberg, M.D., Ph.D. Director, Center for Neurotechnology and Neurorecovery, Department of Neurology, Massachusetts General Hospital, Harvard Medical School Professor of Engineering, Brown University Director, VA RR&D Center for Neurorestoration and Neurotechnology, Providence VAMC Wednesday, February 24, 2021 12:00 […]
Suppressing Neuroinflammation in Neurodegenerative Diseases – Cell Therapy of Immune-mediated Dysfunction
VirtualNeuroinflammation is a major driving force in the pathophysiology of the neurodegenerative diseases ALS and Alzheimer Disease. Such neuroinflammation is characterized by alterations of the immune system - primarily the presence of pro-inflammatory macrophages and microglia, as well as dysfunctional regulatory T-lymphocytes (known as Tregs). Together these promote neuronal degeneration and contribute significantly to the […]